Interim results for the period ended 30 June 2020
(World News Science)

4D pharma plc Interim Report 2020 Leading the development of Live Biotherapeutics Pioneering a revolutionary class of medicines: Live Biotherapeutic products What we do 4D was established with the mission of leveraging the deep and varied interactions between the human body and the gut microbiome - the trillions of bacteria that colonise the human gastrointestinal tract - to develop an entirely novel class of drug: Live Biotherapeutics. We are focussed on understanding how individual strains of bacteria function and how their interactions with the human host can be exploited to treat particular diseases, from cancer to asthma to conditions of the central nervous system. 4dpharmaplc.com...